These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 12236804)

  • 1. Cost-effectiveness comparison of tizanidine and baclofen in the management of spasticity.
    Rushton DN; Lloyd AC; Anderson PM
    Pharmacoeconomics; 2002; 20(12):827-37. PubMed ID: 12236804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost analysis of the treatment of severe spinal spasticity with a continuous intrathecal baclofen infusion system.
    Postma TJ; Oenema D; Terpstra S; Bouma J; Kuipers-Upmeijer H; Staal MJ; Middel BJ
    Pharmacoeconomics; 1999 Apr; 15(4):395-404. PubMed ID: 10537958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An approach to switching patients from baclofen to tizanidine.
    Brenner R; Hyman N; Knobler R; O'Brien M; Stephan T
    Hosp Med; 1998 Oct; 59(10):778-82. PubMed ID: 9850294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional benefits and cost/benefit analysis of continuous intrathecal baclofen infusion for the management of severe spasticity.
    Sampson FC; Hayward A; Evans G; Morton R; Collett B
    J Neurosurg; 2002 Jun; 96(6):1052-7. PubMed ID: 12066906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis.
    Smolenski C; Muff S; Smolenski-Kautz S
    Curr Med Res Opin; 1981; 7(6):374-83. PubMed ID: 7016449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative profile of tizanidine in the management of spasticity.
    Lataste X; Emre M; Davis C; Groves L
    Neurology; 1994 Nov; 44(11 Suppl 9):S53-9. PubMed ID: 7970011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis.
    Eyssette M; Rohmer F; Serratrice G; Warter JM; Boisson D
    Curr Med Res Opin; 1988; 10(10):699-708. PubMed ID: 3286128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tizanidine treatment of spasticity: a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam.
    Groves L; Shellenberger MK; Davis CS
    Adv Ther; 1998; 15(4):241-51. PubMed ID: 10186943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of intrathecal baclofen therapy for the treatment of severe spasticity associated with cerebral palsy.
    de Lissovoy G; Matza LS; Green H; Werner M; Edgar T
    J Child Neurol; 2007 Jan; 22(1):49-59. PubMed ID: 17608306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatments for spasticity and pain in multiple sclerosis: a systematic review.
    Beard S; Hunn A; Wight J
    Health Technol Assess; 2003; 7(40):iii, ix-x, 1-111. PubMed ID: 14636486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind, long-term study of tizanidine ('Sirdalud') in spasticity due to cerebrovascular lesions.
    Medici M; Pebet M; Ciblis D
    Curr Med Res Opin; 1989; 11(6):398-407. PubMed ID: 2651016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of Intrathecal Baclofen Therapy in severe refractory non-focal disabling spasticity: a Spanish hospital perspective.
    Vidal J; Slof J; Serrano D; Marqués T; Kumru H; Benito-Penalva J
    Expert Rev Pharmacoecon Outcomes Res; 2017 Feb; 17(1):67-76. PubMed ID: 27142176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological interventions for spasticity following spinal cord injury: results of a Cochrane systematic review.
    Taricco M; Pagliacci MC; Telaro E; Adone R
    Eura Medicophys; 2006 Mar; 42(1):5-15. PubMed ID: 16565680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients.
    Hoogstraten MC; van der Ploeg RJ; vd Burg W; Vreeling A; van Marle S; Minderhoud JM
    Acta Neurol Scand; 1988 Mar; 77(3):224-30. PubMed ID: 3376747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness modeling of intrathecal baclofen therapy versus other interventions for disabling spasticity.
    Bensmail D; Ward AB; Wissel J; Motta F; Saltuari L; Lissens J; Cros S; Beresniak A
    Neurorehabil Neural Repair; 2009; 23(6):546-52. PubMed ID: 19228818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical cost impact of intrathecal baclofen therapy for severe spasticity.
    Saulino M; Guillemette S; Leier J; Hinnenthal J
    Neuromodulation; 2015 Feb; 18(2):141-9; discussion 149. PubMed ID: 25145312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological interventions for spasticity following spinal cord injury.
    Taricco M; Adone R; Pagliacci C; Telaro E
    Cochrane Database Syst Rev; 2000; 2000(2):CD001131. PubMed ID: 10796750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury.
    Kamen L; Henney HR; Runyan JD
    Curr Med Res Opin; 2008 Feb; 24(2):425-39. PubMed ID: 18167175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Summary of combined clinical analysis of controlled clinical trials with tizanidine.
    Wallace JD
    Neurology; 1994 Nov; 44(11 Suppl 9):S60-8; discussion S68-9. PubMed ID: 7970013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper.
    Otero-Romero S; Sastre-Garriga J; Comi G; Hartung HP; Soelberg Sørensen P; Thompson AJ; Vermersch P; Gold R; Montalban X
    Mult Scler; 2016 Oct; 22(11):1386-1396. PubMed ID: 27207462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.